Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P244

ECE2006 Poster Presentations Cytokines and growth factors (33 abstracts)

CD4 T-cell count improves during sustained IGF-I response following low dose growth hormone therapy in HIV-infected patients on stable antiretroviral regimens. A pilot study

O Andersen 1 , BR Hansen 2 , A Flyvbjerg 3 , S Madsbad 4 , H Ørskov 3 , JO Nielsen 1 , J Iversen 1 & SB Haugaard 2


1Dept. of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark; 2Clinical Research Unit, Hvidovre University Hospital, Hvidovre, Copenhagen, Denmark; 3Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus, Denmark; 4Dept. of Endocrinology and Internal Medicine, Hvidovre, Copenhagen, Denmark.


Objective: High dose growth hormone (rhGH) regimens (2 to 4 mg/day) have been shown to increase circulating insulin-like growth factor (IGF)-I to supra-physiological levels in human immunodeficiency virus (HIV)-infected patients on combined antiretroviral therapy (CART). This setting may improve immunologic output. However, a high plasma IGF-I concentration has detrimental effects on glucose metabolism, which hampers the use of high dose rhGH regimens.

Methods: We have reported previously on a group of 6 HIV-infected patients on stable CART (>28 months), in whom 16 weeks on rhGH 0.7 mg/day increased total (+117%, P<0.01) and free (+155%, P<0.01) IGF-I to high in physiological range. This study was extended to examine whether continued use of low-dose rhGH (0.7 mg/day until week 60; 0.4 mg/day from week 60 to week 140) would keep IGF-I expediently high in the normal range and improve CD4 T-cell response.

Results: Total and free IGF-I remained expediently increased at week 36 (+97%, P<0.01 and +125%, P<0.01) and week 60 (+77%, P=0.01 and +125%, P<0.01) compared to baseline (161±15 μg/l and 0.75±0.11 μg/l). CD4 T-cell count, which was unchanged after 16 weeks (P>0.7), was increased at week 36 (+15%, P<0.05) and week 60 (+31%, P=0.01), compared to baseline (CD4 456±55 cells/μl). After rhGH dose-reduction, total IGF-I remained increased at week 88 (+44%, P=0.01) and week 140 (+46%, P=0.07) compared to baseline, whereas free IGF-I returned to baseline (P>0.3). CD4 cell count remained increased at week 88 (+33%, P<0.01) and week 140 (+36%, P=0.02) compared to baseline.

Conclusions: These data suggest that a low-dose rhGH regimen through a substantial increment in circulating IGF-I may improve immunologic response in terms of increased CD4 T-cell output in HIV-infected patients on stable CART. A well-powered, randomized, double-blind, placebo-controlled clinical trial is ongoing aiming to validate these preliminary data.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.